Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:

Sponsor
University of Michigan (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05370404
Collaborator
(none)
250
1
2
3
83.6

Study Details

Study Description

Brief Summary

This is a research project in which two standard of care practices will be evaluated to examine the difference in outcomes. The goal is to improve patient care and safety. One group will receive prescriptions for acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and magnesium. The other group will receive the recommendation to take acetaminophen, NSAIDs, and magnesium as over-the-counter drugs in the same dosage as the prescription group. The same doses and routes for non-opioid medications will be used in both groups.

Condition or Disease Intervention/Treatment Phase
  • Other: Prescription by surgical team
  • Other: Recommendation by surgical team
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
250 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: A Project on Non-Opioid Pain Medication Use After Discharge From Elective Surgery
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Prescription Group for acetaminophen, NSAIDs, and magnesium

Participants will receive prescriptions from the surgical team for non-opioid pain medications to take at home after discharge from surgery. The non-opioid pain medications will be acetaminophen 1000 milligram (mg) four times a day (qid) for 3 days then as needed (prn) pain, ibuprofen 600 mg qid for 3 days then prn, and magnesium oxide 400 mg daily prn pain.

Other: Prescription by surgical team
The surgical team prescribes medications to the patient

Active Comparator: Over the Counter Group

Participants will receive a recommendation from the surgical team to take over-the-counter non-opioid pain medications at home after discharge from surgery. The non-opioid pain medications will be acetaminophen 1000 mg qid for 3 days then prn pain, ibuprofen 600 mg qid for 3 days then prn, and magnesium oxide 400 mg daily prn pain.

Other: Recommendation by surgical team
The surgical team recommends the patient to take over-the-counter medications

Outcome Measures

Primary Outcome Measures

  1. Maximal consumption of acetaminophen and NSAIDs within 3 days after discharge from surgery [3 days following surgery discharge]

    Patient report of the number of doses within the first 3 days of the use of both acetaminophen and NSAID at home after discharge from surgery. Patients are anticipated to take up to 4 doses of acetaminophen and NSAIDs per day. Over 3 days, patients would be anticipated to take a maximum of 12 doses. This outcome is a count that ranges from 0 (no doses of acetaminophen plus NSAIDs) to 12.

  2. Patient use of acetaminophen within 3 days after discharge from surgery [3 days following surgery discharge]

    Patient-reported use of acetaminophen at any point in time within the first 3 days at home after discharge from surgery.

  3. Patient use of NSAIDS within 3 days after discharge from surgery [3 days following surgery discharge]

    Patient-reported use of NSAIDs at any point in time within the first 3 days at home after discharge from surgery.

  4. Patient use of acetaminophen and NSAID with opioid within 3 days after discharge from surgery [3 days following surgery discharge]

    Patient-reported use of both acetaminophen and NSAID on every day oral pain medication is taken within the first 3 days at home after discharge from surgery.

  5. Delayed acetaminophen and NSAID use as reported at 12-16 days after discharge from surgery [12-16 days following surgery discharge]

    Patient-reported use of acetaminophen and/or NSAIDs in the second week after discharge from surgery.

Secondary Outcome Measures

  1. Patient-reported consumption of opioid pills within 3 days after discharge from surgery [3 days following surgery discharge]

    The total amount of opioids consumed over days 0-3 after discharge from surgery will be compared between the two groups.

  2. Patient-reported consumption of opioid pills as reported at 12-16 days after discharge from surgery [12-16 days following surgery discharge]

    The total amount of opioids consumed over the second week after discharge from surgery will be compared between the two groups.

  3. Pain intensity at site of surgery 3 days following surgery discharge [3 days following surgery discharge]

    This is a one question survey in which the participants are asked to rate the pain at the site of the surgery that best describes the pain from a scale of 0 (no pain) to 10 (pain is the worst). Trends in worst pain intensity over days 0-3 after discharge from surgery will be compared between the two groups.

  4. Pain intensity at site of surgery as reported at 12-16 days following surgery discharge [3 days following surgery discharge]

    This is a one question survey in which the participants are asked to rate the pain at the site of the surgery that best describes the pain from a scale of 0 (no pain) to 10 (pain is the worst). Trends in worst pain intensity over the second week after discharge from surgery will be compared between the two groups.

  5. Medication side effects within 3 days following surgery discharge [3 days following surgery discharge]

    Patient report of common analgesic related side effects will be measured using the Medicare symptom checklist. Composite report of any side effect over days 0-3 after discharge from surgery will be compared between the two groups.

  6. Patient satisfaction with pain treatment within 3 days following surgery discharge [3 days following surgery discharge]

    This is a one question survey in which the participants are asked to rate the satisfaction for pain management with a scale from very dissatisfied to very satisfied. Patient report of overall satisfaction with the postoperative pain treatment over days 0-3 after discharge from surgery will be compared between the two groups.

  7. Patient use of magnesium within 3 days after discharge from surgery [3 days following surgery discharge]

    Patient-reported use of magnesium at any point in time within the first 3 days at home after discharge from surgery.

  8. Delayed magnesium use days as reported at 12-16 days after discharge from surgery [12-16 days following surgery discharge]

    Patient-reported use of magnesium in the second week after discharge from surgery.

Other Outcome Measures

  1. Opioid disposal [3-16 days following surgery discharge]

    Patient-reported disposal of opioids after completion of therapy

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Anticipated to be prescribed and use an opioid medication to treat acute pain after elective outpatient surgery
Exclusion Criteria:
  • Contraindications to taking acetaminophen or NSAIDs

  • Significant analgesic medication use before surgery

  • Inability to receive emails or phone calls for follow up assessment

  • Patients who have reoperation, another surgery, or experience complications within 14 days after surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Michigan Ann Arbor Michigan United States 48109

Sponsors and Collaborators

  • University of Michigan

Investigators

  • Principal Investigator: Mark Bicket, MD, University of Michigan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mark Bicket, MD, PhD, Assistant Professor, University of Michigan
ClinicalTrials.gov Identifier:
NCT05370404
Other Study ID Numbers:
  • HUM00203454
First Posted:
May 11, 2022
Last Update Posted:
Aug 10, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mark Bicket, MD, PhD, Assistant Professor, University of Michigan
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 10, 2022